<DOC>
	<DOCNO>NCT00045461</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Hyperthermia therapy kill tumor cell heat several degree body temperature . Combining hyperthermia chemotherapy may kill tumor cell . It yet know chemotherapy effective without whole-body hyperthermia therapy treat gynecologic cancer . PURPOSE : Randomized phase II/III trial compare effectiveness chemotherapy without whole-body hyperthermia treat patient recurrent ovarian epithelial , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Whole-Body Hyperthermia Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare time progressive disease patient recurrent ovarian epithelial , fallopian tube , extraovarian peritoneal cancer treat carboplatin ifosfamide without whole body hyperthermia . - Compare response rate , duration response , survival time patient treat regimen . - Compare effect presence disseminate tumor cell bone marrow patient treat regimen . - Compare toxicity regimens patient . - Assess quality life patient treat regimen . OUTLINE : This phase II safety efficacy study follow phase III randomize , open-label , multicenter study . - Phase II : Patients receive ifosfamide IV 1 hour carboplatin IV 20 minute day 1 . Patients also undergo whole body hyperthermia least 1 hour day 1 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Phase III ( successful treatment 15 patient phase II ) : Patients stratify accord disease-free interval ( 6-12 month v 12 month ) , measurable disease ( bidimensionally measurable v measurable clinical mean ) , disease recurrence ( first recurrence v second great recurrence ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive ifosfamide , carboplatin , whole body hyperthermia phase II . - Arm II : Patients receive ifosfamide carboplatin arm I . - In arm , treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Quality life assess course , 4 week last course , every 3 month 2 year . Patients follow 4 week every 3 month 2 year . PROJECTED ACCRUAL : A total 15 patient accrue phase II study . A total 226 patient ( 113 per treatment arm ) accrue phase III study within 2 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , extraovarian peritoneal cancer Recurrent disease ( FIGO stage ) Not amenable curative surgery radiotherapy alone Failed prior primary platinumbased therapy least 6 month therapy discontinuation Measurable lesion CT scan , MRI , chest xray , sonography Physical examination allow document lymph node skin metastases Physical gynecological examination allow welldefined palpable tumor lesion Increase CA 125 without measurable tumor acceptable indication recurrence No CNS metastases No tumor borderline malignancy PATIENT CHARACTERISTICS : Age 18 65 Performance status ECOG 02 Life expectancy At least 24 week Hematopoietic Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic Not specify Renal Creatinine clearance least 60 mL/min No chronic acute renal failure Cardiovascular Cardiovascular function sufficient hyperthermia treatment stressECG No cardiomyopathy impair ventricular function No New York Heart Association class III IV heart disease No cardiac arrhythmia influence LVEF require medication No myocardial infarction angina pectoris within past 6 month No uncontrolled arterial hypertension Pulmonary Pulmonary function sufficient hyperthermia treatment pulmonary function test Other No untreated endocrinological disease ( e.g. , hyperthyroidism diabetes mellitus ) No primary malignancy except carcinoma situ cervix adequately treat basal cell skin cancer No contraindication hyperthermia treatment ( e.g. , photodermatosis , history malignant hyperthermia , claustrophobia ) No hypersensitivity carboplatin , ifosfamide , study medication Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No concurrent cytotoxic antineoplastic therapy Endocrine therapy Concurrent hormone replacement therapy allow Concurrent steroid antiemetic allow Radiotherapy See Disease Characteristics At least 1 year since prior radiotherapy ( tumoricidal dose ) pelvis Concurrent palliative local radiotherapy painful ( nonprogressive ) exist lesion allow measurable site present No concurrent radiotherapy second exist lesion Surgery See Disease Characteristics Other No prior form hyperthermic therapy At least 3 week since medication part another clinical study At least 3 week since prior investigational agent At least 6 week since prior betablockers No concurrent photosensitize drug No concurrent betablockers No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>